Advertisement
Australia markets closed

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • AUD/USD

    0.6418
    -0.0008 (-0.12%)
     

  • OIL

    82.94
    +0.21 (+0.25%)
     

  • GOLD

    2,409.50
    +11.50 (+0.48%)
     

  • Bitcoin AUD

    100,097.94
    +1,149.14 (+1.16%)
     

  • CMC Crypto 200

    1,373.62
    +61.00 (+4.65%)
     

  • AUD/EUR

    0.6026
    -0.0005 (-0.08%)
     

  • AUD/NZD

    1.0897
    +0.0022 (+0.21%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,097.48
    -296.84 (-1.71%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,896.30
    +120.92 (+0.32%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Windtree Therapeutics
·2-min read

WARRINGTON, Pa., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser, President and Chief Executive Officer, will present a corporate overview and be available for 1x1 meetings at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit.

The Company’s presentation will take place on Wednesday, September 22, 2021 at 9:55 am ET. A live webcast and replay of the presentation will be available on the Investor Events page (https://ir.windtreetx.com/events) of the company’s website (www.windtreetx.com).

About Windtree Therapeutics
Windtree Therapeutics, Inc. is advancing multiple late-stage interventions for acute cardiovascular and acute pulmonary disorders to treat patients in moments of crisis. Using new scientific and clinical approaches, Windtree is developing a multi-asset franchise anchored around compounds with an ability to activate SERCA2a, with lead candidate, istaroxime, being developed as a first-in-class treatment for acute heart failure and for early cardiogenic shock. Windtree’s heart failure platform includes follow-on oral pre-clinical SERCA2a activator assets as well. In pulmonary care, Windtree has focused on developing AEROSURF®, a drug-device combination, to deliver its synthetic KL4 surfactant non-invasively to premature infants with respiratory distress syndrome, and is facilitating transfer of clinical development of AEROSURF® to its licensee in Asia, Lee's HK. Windtree is also evaluating KL4 surfactant for the treatment of acute respiratory distress syndrome in COVID-19 patients. Also in Windtree’s portfolio is rostafuroxin, a novel precision drug product targeting hypertensive patients with certain genetic profiles.

For more information, please visit the Company's website at www.windtreetx.com.

Contact Information:
Monique Kosse
LifeSci Advisors
212.915.3820 or monique@lifesciadvisors.com

Media contact:
Andrew Mielach
LifeSci Communications
646.876.5868 or amielach@lifescicomms.com